StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3023% above fair value
$435.64−3.18 (-0.72%)

Close on Nov 20, 2026Market cap $235.52BP/E 25.3Yield 2.22%

Amgen Median Employee Annual Total Compensation by Year

Median Employee Annual Total Compensation ($) ($)

Amgen Median Employee Annual Total Compensation: $154,123 in FY2025, down 3.7% from a year earlier.

Latest, FY2025
154,123
Period ended Dec 31, 2025
Change on a year earlier
-3.7%
160,017 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below

Where the FY2025 figure comes from

“We then determined the annual total compensation of our median employee for 2025 which was $154,123. As disclosed in the “Summary Compensation Table” appearing on page 83, our CEO’s annual total compensation for 2025 was $24,693,120. Based on the foregoing, the ratio of the annual total compensation of our CEO to that of the median staff member was 160 to 1.”

Source: Proxy Statement (DEF 14A) (d13946ddef14a.htm, filed 2026-04-07) ↗

Reported in DEF 14A Proxy Statement — CEO Pay Ratio Disclosure.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Amgen Median Employee Annual Total Compensation ($), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/proxy-median-emp

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?